Bias in intervention studies that enroll patients from high-risk clinics.

Abstract excerpt

It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer. However, some studies that evaluate the effects of interventions designed to reduce risk in mutation carriers may be susceptible to a serious selection bias...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Ambulatory Care Facilities
• Share to Clinical Trials as Topic
• Share to Genes, BRCA1